ArticleInternational journal of women's health2025
Risk Factors for Sarcopenia in Women with Type 2 Diabetes and the Effects of Metformin: A Cross-Sectional Study of 7,731 Patients from the UK Biobank.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the sarcopenia risk factors and the association between metformin use and sarcopenia in female patients with Type 2 diabetes mellitus (T2DM) through a cross-sectional analysis of data from the UK Biobank. Methods: In a cross-sectional analysis of 7,731 women with T2DM from the UK Biobank, participants were categorized into nonsarcopenia, probable sarcopenia, and sarcopenia groups based on the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. Logistic regression models were employed to investigate the association between metformin use and sarcopenia, adjusting for age, education, physical activity, and comorbidities. Results: The prevalence of probable sarcopenia and sarcopenia was 16.2% and 3.4%, respectively, with rates increasing with age. Metformin use was significantly associated with a higher risk of sarcopenia (adjusted OR 1.13; 95% CI 1.01-1.26). This association remained consistent across various subgroups, including different age ranges and levels of physical activity. Conclusion: Metformin use was cross-sectionally associated with higher odds of sarcopenia, particularly in older women with low physical activity and comorbidities. These findings highlight the need for further longitudinal and mechanistic studies to confirm the relationship and explore potential underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.